STOCK TITAN
  1. Home
  2. Sec-filings
  3. TGTX
  4. [Form 4] TG THERAPEUTICS, INC. Insider Trading Activity

Director at TG Therapeutics (TGTX) granted 8,325 stock tracking units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

TG Therapeutics director Laurence N. Charney received a grant of 8,325 Stock Tracking Units on June 11, 2026. These units were awarded as compensation and carry no exercise price.

Each Stock Tracking Unit represents a contingent right, at the discretion of the plan committee, to receive either one share of TG Therapeutics common stock or a cash payment equal to the fair market value of one share. This payment or share delivery is scheduled no later than 30 days after the first anniversary of the grant date, provided Charney remains in continuous service through that vesting date.

Following this award, Charney holds 8,325 Stock Tracking Units directly, each tied to an equivalent number of underlying common shares. The transaction does not involve any open-market buying or selling, and reflects a routine equity-based incentive grant.

Positive

  • None.

Negative

  • None.
Insider Charney Laurence N
Role null
Type Security Shares Price Value
Grant/Award Stock Tracking Unit 8,325 $0.00 --
Holdings After Transaction: Stock Tracking Unit — 8,325 shares (Direct, null)
Footnotes (1)
  1. Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant. Provided the Reporting Person remains in continuous service with the Issuer through the Vesting Date, the STUs shall vest upon the first anniversary of the date of grant.
Stock Tracking Units granted 8,325 units Grant to director on June 11, 2026
Underlying common shares 8,325 shares Each unit tied to one common share
Exercise price per unit $0.00 Grant/award acquisition, no exercise cost
Settlement deadline 30 days after first anniversary Settlement in stock or cash post-vesting
Total units after transaction 8,325 units Director’s direct holdings following grant
Stock Tracking Unit financial
"Each stock tracking unit ("STU") represents a contingent right to receive either..."
contingent right financial
"represents a contingent right to receive either (i) one share... or (ii) a cash payment..."
fair market value financial
"a cash payment equal to the fair market value of one share of the Issuer's common stock"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
Vesting Date financial
"Provided the Reporting Person remains in continuous service with the Issuer through the Vesting Date..."
continuous service financial
"Provided the Reporting Person remains in continuous service with the Issuer through the Vesting Date..."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Charney Laurence N
(Last)(First)(Middle)
3020 CARRINGTON MILL BLVD, SUITE 475
(Street)
MORRISVILLE NORTH CAROLINA 27560
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
TG THERAPEUTICS, INC. [ TGTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Tracking Unit(1)06/11/2026A8,325 (2) (2)Common Stock8,325$08,325D
Explanation of Responses:
1. Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant.
2. Provided the Reporting Person remains in continuous service with the Issuer through the Vesting Date, the STUs shall vest upon the first anniversary of the date of grant.
/s/ Laurence N. Charney06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did TG Therapeutics (TGTX) director Laurence N. Charney report in this Form 4?

Laurence N. Charney reported receiving 8,325 Stock Tracking Units as a grant. The award was made on June 11, 2026, carries no exercise price, and represents equity-based compensation rather than an open-market share purchase or sale.

How many Stock Tracking Units were granted to the TG Therapeutics (TGTX) director?

The director received 8,325 Stock Tracking Units. Each unit is linked to an equivalent number of underlying TG Therapeutics common shares, giving the holder a potential claim on 8,325 shares or the cash value of those shares at settlement.

What does each Stock Tracking Unit in the TG Therapeutics (TGTX) grant represent?

Each Stock Tracking Unit represents a contingent right to value equal to one common share. At the plan committee’s discretion, this can be settled in either one share of TG Therapeutics common stock or a cash payment equal to that share’s fair market value.

When do the TG Therapeutics (TGTX) Stock Tracking Units granted to the director vest and pay out?

The Stock Tracking Units vest on the first anniversary of the grant date. Provided the director remains in continuous service through that vesting date, settlement in shares or cash must occur no later than 30 days after the first anniversary of the grant.

Is the TG Therapeutics (TGTX) director’s Form 4 transaction a market purchase or sale of shares?

No, the filing reflects a grant of Stock Tracking Units, not a market trade. The director did not buy or sell shares on the open market; instead, he received equity-based compensation with potential future settlement in stock or cash.

How many TG Therapeutics (TGTX) Stock Tracking Units does the director hold after this grant?

After the transaction, the director holds 8,325 Stock Tracking Units directly. This equals the full amount granted in the filing, and these units are tied to an equivalent number of underlying TG Therapeutics common shares for future settlement.